Advertisement

Journal of Genetics

, 98:1 | Cite as

Association of polymorphisms of CYP11B2 gene –344C/T and ACE gene I/D with antihypertensive response to angiotensin receptor blockers in Chinese with hypertension

  • Hongtao GongEmail author
  • Liying Mu
  • Tong Zhang
  • Xiuying Xu
  • Fenghe Du
Research Article
  • 10 Downloads

Abstract

The aim of this study was to determine whether the polymorphism of aldosterone synthase (CYP11B2) –344C/T and angiotensin-converting enzyme (ACE) insertion/deletion (I/D) were associated with the response of blood pressure (BP) to telmisartan treatment. After a two-week single-blind placebo run-in period, 148 patients with mild-to-moderate primary hypertension received monotherapy of telmisartan with 80 mg/day and then were followed up for eight weeks. Polymorphisms of CYP11B2 –344C/T and ACE I/D gene were determined through polymerase chain reaction-restriction fragment polymorphism analysis. The relationship between these polymorphisms and changes in BP was monitored and evaluated after eight weeks of treatment. With respect to the polymorphism of CYP11B2 –344C/T, the reduction in diastolic BP was significantly greater in patients carrying the C allele (CC+CT) compared with those carrying the TT genotype. There was no significant differences between ACE I/D polymorphism and BP reduction after treatment. We concluded that the aldosterone synthase –344C/T polymorphism was related to the antihypertensive treatment with telmisartan in hypertensive patients.

Keywords

essential hypertension aldosterone synthase angiotensin-converting enzyme single-nucleotide polymorphism angiotensin receptor blocker 

Notes

Acknowledgement

Research supported by the Sino-German Laboratory for Molecular Medicine, FuWai Cardiovascular Hospital and Cardiovascular Institute, China.

References

  1. Alvarez-Madrazo S., Mackenzie S. M., Davies E., Fraser R., Lee W. K., Brown M. et al. 2013 Common polymorphisms in the CYP11B1 and CYP11B2 genes: evidence for a digenic influence on hypertension. Hypertension 61, 232–239.PubMedCrossRefGoogle Scholar
  2. Boduła A., Dołyk A., Protasiewicz J. and Adamiec R. 2007 The role of the –344C/T polymorphism of the aldosterone synthase gene (CYP11B2) in cardiovascular diseases. Postepy Hig. Med. Dosw. 61, 838–847.Google Scholar
  3. Brand E., Chatelain N., Mulatero P., Féry I., Curnow K., Jeunemaitre X. et al. 1998 Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 32, 198–204.PubMedCrossRefGoogle Scholar
  4. Cheng X. and Xu G. 2009 Association between aldosterone synthase CYP11B2 polymorphism and essential hypertension in Chinese: a meta-analysis. Kidney Blood Press. Res. 32, 128–140.PubMedCrossRefGoogle Scholar
  5. Choi H. D., Suh J. H., Lee J. Y., Bae S. K., Kang H. E., Lee M. G. et al. 2013 Effects of ACE and ADD1 gene polymorphisms on blood pressure response to hydrochlorothiazide: a meta-analysis. Int. J. Clin. Pharmacol. Ther. 51, 718–724.PubMedCrossRefGoogle Scholar
  6. Do A. N., Irvin M. R., Lynch A. I., Claas S. A., Boerwinkle E., Davis B. R. et al. 2014 The effects of angiotensinogen gene polymorphisms on cardiovascular disease outcomes during antihypertensive treatment in the GenHAT study. Front. Pharmacol. 5, 210.PubMedPubMedCentralCrossRefGoogle Scholar
  7. Fardella C. E., Rodriguez H., Montero J., Zhang G., Vignolo P., Rojas A. et al. 1996 Genetic variation in P450c 11AS in Chilean patients with low rennin hypertension. J. Clin. Endocrinol. Metab. 81, 4347–4351.PubMedGoogle Scholar
  8. Gupta S., Chattopadhyaya I., Agrawal B. K., Sehajpal P. K. and Goel R. K. 2015 Correlation of renin angiotensin system (RAS) candidate gene polymorphisms with response to Ramipril in patients with essential hypertension. J. Postgrad. Med. 61, 21–26.PubMedPubMedCentralCrossRefGoogle Scholar
  9. Kim H. K., Lee H., Kwon J. T. and Kim H. J. 2015 A polymorphism in AGT and AGTR1 gene is associated with lead-related high blood pressure. J. Renin Angiotensin Aldosterone Syst. 16, 712–719.PubMedCrossRefGoogle Scholar
  10. Kupari M., Hautanen A., Lankinen L., Koskinen P., Virolainen J., Nikkila H. et al. 1998 Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 97, 569–575.PubMedCrossRefGoogle Scholar
  11. Laragh J. H., Lamport B., Sealey J. and Alderman M. H. 1988 Diagnosis ex juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension 12, 223–226.PubMedCrossRefGoogle Scholar
  12. Li Y., Yang P., Wu S. L., Yuan J. X., Wu Y., Zhao D. D. et al. 2012 Effect of CYP11B2 gene -344 T/C polymorphism on renin-angiotensin-aldosterone system activity and blood pressure response to hydrochlorothiazide. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 29, 68–71.PubMedGoogle Scholar
  13. Lind L., Berne C., Anderssno P. E., Hänni A. and Lithell H. 1995 Is insulin resistance a predictor of the blood pressure response to anti-hypertensive treatment? J. Hum. Hypertens. 9, 759–763.PubMedGoogle Scholar
  14. Liu D. X., Zhang Y. Q., Hu B., Zhang J. and Zhao Q. 2015 Association of AT1R polymorphism with hypertension risk: an update meta-analysis based on 28,952 subjects. J. Renin Angiotensin Aldosterone Syst. 16, 898–909.PubMedCrossRefGoogle Scholar
  15. Materson B. J. 2004 Variability in response to antihypertensive drug treatment. Hypertension 43, 1166–1167.PubMedCrossRefGoogle Scholar
  16. Patnaik M., Pati P., Swain S. N., Mohapatra M. K., Dwibedi B., Kar S. K. et al. 2014 Association of angiotensin-converting enzyme and angiotensin-converting enzyme-2 gene polymorphisms with essential hypertension in the population of Odisha, India. Ann. Hum. Biol. 41, 145–152.PubMedCrossRefGoogle Scholar
  17. Preston R. A., Materson B. J., Reda D. J., Williams D. W., Hamburger R. J., Cushman W. C. et al. 1998 Age-race subgroup compared with rennin profile as predictors of blood pressure response to antihypertensive therapy. JAMA 280, 1168–1172.PubMedCrossRefGoogle Scholar
  18. Suonsyrjä T., Hannila-Handelberg T., Fodstad H., Donner K., Kontula K. and Hiltunen T. P. 2009 Renin-angiotensin system and alpha-adducin gene polymorphisms and their relation to responses to antihypertensive drugs: results from the GENRES study. Am. J. Hypertens. 22, 169–175.PubMedCrossRefGoogle Scholar
  19. Taverne K., de Groot M., de Boer A. and Klungel O. 2010 Genetic polymorphisms related to the renin-angiotensin-aldosterone system and response to antihypertensive drugs. Expert Opin. Drug Metab. Toxicol. 6, 439–460.PubMedCrossRefGoogle Scholar
  20. Tiret L., Rigat B., Visviks S., Breda C., Corvol P., Cambien F. et al. 1992 Evidence from combined segregation and linkage analysis that a variant of the ACE gene controls plasma levels. Am. J. Hum. Genet. 1, 197–205.Google Scholar
  21. Venter J. C., Adams M. D., Myers E. W., Li P. W., Mural R. J., Sutton G. G. et al. 2001 The sequence of the human genome. Science 291, 1304–1351.PubMedCrossRefGoogle Scholar
  22. White P. C. and Slutsker L. 1995 Haplotype analysis of CYP11B2. Endocr. Res. 21, 437–442.PubMedCrossRefGoogle Scholar
  23. Yu H. M., Lin S. G., Liu G. Z., Zhang Y. Q., Ma W. J. and Deng C. Y. 2006 Associations between CYP11B2 gene polymorphisms and the response to angiotensin-converting enzyme inhibitors. Clin. Pharmacol. Ther. 79, 581–589.PubMedCrossRefGoogle Scholar

Copyright information

© Indian Academy of Sciences 2019

Authors and Affiliations

  1. 1.Department of Cardiology, Beijing Tiantan HospitalCapital University of Medical ScienceBeijingPeople’s Republic of China

Personalised recommendations